221 filings
Page 3 of 12
8-K
si79frbtupezomh
29 Mar 22
Departure of Directors or Certain Officers
4:31pm
8-K
n91ma3 qwb5qp8d
24 Mar 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:31pm
POS AM
odiyu1x1uahiqu oovyo
22 Mar 22
Prospectus update (post-effective amendment)
4:30pm
POSASR
yi19k6dw59 nnl
16 Mar 22
Automatic shelf registration (post-effective amendment)
5:21pm
8-K
jj4qmo 486obr0p1jf
16 Mar 22
Athenex Provides Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
5:18pm
8-K
txd8y l4q5devde1v
22 Feb 22
Athenex Announces Appointment of Chief Financial Officer
4:16pm
8-K
gtfh q4e7vc1mgsm
15 Feb 22
Athenex Announces Completion of Sale of Dunkirk Manufacturing Facility
9:00am
8-K
epxob
21 Jan 22
Entry into a Material Definitive Agreement
4:16pm
8-K
wqrk1mou1f
12 Jan 22
Athenex Announces Agreement with ImmunityBio Regarding Dunkirk Manufacturing Facility
8:36am
8-K
n249fmt7wtkm24
28 Dec 21
Departure of Directors or Certain Officers
4:16pm
8-K
4n1y3toshayaypa5la
4 Nov 21
Athenex Provides Third Quarter 2021 Corporate and Financial Update
7:05am
8-K
ksks2d
12 Oct 21
Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel + Encequidar in Metastatic Breast Cancer
6:31am
8-K
pdk55
3 Sep 21
Departure of Directors or Certain Officers
7:16am
8-K
0fjcqjeinlp
20 Aug 21
Entry into a Material Definitive Agreement
5:20pm
424B5
eaewnib72 w4y
20 Aug 21
Prospectus supplement for primary offering
5:19pm
424B5
rf00ffouewswt2pz
16 Aug 21
Prospectus supplement for primary offering
5:27pm
EFFECT
cdr80t
13 Aug 21
Notice of effectiveness
12:15am
CORRESP
zpf0qfc6 ep0w
10 Aug 21
Correspondence with SEC
12:00am